Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia.

Simple item page
dc.contributor.authorRishi, Pukhraj
dc.contributor.authorRishi, Ekta
dc.contributor.authorVenkataraman, Anusha
dc.contributor.authorGopal, Lingam
dc.contributor.authorSharma, Tarun
dc.contributor.authorBhende, Muna
dc.contributor.authorRatra, Dhanashree
dc.contributor.authorSen, Pratik Ranjan
dc.contributor.authorSen, Parveen
dc.date.accessioned2011-12-30T03:56:55Z
dc.date.available2011-12-30T03:56:55Z
dc.date.issued2011-05
dc.description.abstractThis retrospective, interventional case series analyses treatment outcomes in eyes with choroidal neovascularization (CNV) secondary to pathological myopia, managed with photodynamic therapy, (PDT), (Group 1, N = 11), PDT and intravitreal triamcinolone acetonide (4 mg/0.1ml) (Group 2, N = 3), PDT and intravitreal anti-vascular endothelial growth factor (anti-VEGF) bevacizumab 1.25 mg/0.05 ml, ranibizumab 0.5 mg/0.05 ml and reduced-fluence PDT and intravitreal ranibizumab 0.5 mg/0.05 ml (Group 3, N=12). All the patients underwent PDT. Intravitreal injections were repeated as required. SPSS 14 software was used to evaluate the data. Wilcoxon signed ranks test was used to evaluate pre- and post-treatment vision. The Kruskal-Wallis test was used for comparison between the groups. All the groups were statistically comparable. All the eyes showed complete regression of CNV, with a minimum follow-up of six months. All groups had visual improvement; significantly in Group 3 (P = 0.003). Combination PDT with anti-VEGF agents appeared to be efficacious in eyes with myopic CNV. However, a larger study with a longer follow-up is required to validate these results.en_US
dc.identifier.citationRishi Pukhraj, Rishi Ekta, Venkataraman Anusha, Gopal Lingam, Sharma Tarun, Bhende Muna, Ratra Dhanashree, Sen Pratik Ranjan, Sen Parveen. Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia. Indian Journal of Ophthalmology. 2011 May; 59(3): 242-246.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/136183
dc.language.isoenen_US
dc.source.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120250/en_US
dc.subjectBevacizumaben_US
dc.subjectchoroidal neovascularizationen_US
dc.subjectintravitreal injectionen_US
dc.subjectmyopiaen_US
dc.subjectphotodynamic therapyen_US
dc.subjectranibizumaben_US
dc.subjecttriamcinolone acetonideen_US
dc.subjectvascular endothelial growth factoren_US
dc.subject.meshAngiogenesis Inhibitors --administration & dosage
dc.subject.meshAntibodies, Monoclonal --administration & dosage
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshChoroidal Neovascularization --drug therapy
dc.subject.meshChoroidal Neovascularization --etiology
dc.subject.meshDrug Therapy, Combination
dc.subject.meshHumans
dc.subject.meshIntravitreal Injections
dc.subject.meshMyopia, Degenerative --complications
dc.subject.meshPhotochemotherapy
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.subject.meshTriamcinolone Acetonide --administration & dosage
dc.titlePhotodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijo2011v59n3p242.pdf
Size:
3.13 MB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Ophthalmology